Evidence map›Paper›PMID 30340465›Full record

SynthesisBMC medical genetics2018

Do polymorphisms in protein kinase catalytic subunit alpha-1 gene associated with cancer susceptibility? a meta-analysis and systematic review.

Jialin Meng, Xinyao Fan, Meng Zhang, Zongyao Hao, Chaozhao Liang

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC medical genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Role ofAmerican journal of men's health
    Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jialin MengDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, No. 218th, Jixi Road, Hefei, 230022, Anhui, China.
Xinyao FanGraduate School of Anhui Medical University, No. 81th, Meishan Road, Hefei, 230032, Anhui, China.
Meng ZhangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, No. 218th, Jixi Road, Hefei, 230022, Anhui, China.
Zongyao HaoDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, No. 218th, Jixi Road, Hefei, 230022, Anhui, China.
Chaozhao LiangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, No. 218th, Jixi Road, Hefei, 230022, Anhui, China. liang_chaozhao@ahmu.edu.cn.ORCID 0000-0003-2317-1323
Anhui University · CNAnhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, several studies have demonstrated that PRKAA1 polymorphisms conduce to the development of cancer. PRKAA1 gene encodes the AMP-activated protein kinase summit-α1, and plays an important role in cell metabolism. Thus, we performed a systematic review and meta-analysis of all enrolled eligible case-control studies to obtain a precise correlation between PRKAA1 polymorphism and cancer susceptibility.

methodsExtensive retrieve was performed in Web of Science, Google Scholar, PubMed, EMbase, CNKI and Wanfang databases up to August 26, 2018. Odds ratios (ORs) and 95% CIs were performed to evaluate the overall strength of the associations in five models, as well as in subgroup analyses, stratified by ethnicity, cancer type or source of control. Q-test, Egger's test and Begg's funnel plot were applied to evaluate the heterogeneity and publication bias. In-silico analysis was performed to demonstrate the relationship of PRKAA1 expression correlated with cancer tissues and survival time.

resultsTwenty-two case-control studies from 14 publications were enrolled, with 17,068 cases and 20,871 controls for rs13361707, and 2514 cases and 3193 controls for rs10074991. Overall, we identified that the PRKAA1 rs13361707 polymorphism is not significantly associated with cancer susceptibility under all five genetic models. For rs10074991, we revealed a significant decrease risk in allelic comparison model (B vs. A: OR = 0.774, 95% CI = 0.642-0.931, P

conclusionsTo sum up, PRKAA1 rs13361707 polymorphism is not participant with the increased risk of cancer, while the A allele of PRKAA1 rs10074991 revealed a significant decrease risk.

Indexed as

Polymorphism, Single NucleotideAllelesAMP-Activated Protein KinasesBreast NeoplasmsCase-Control StudiesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleGene ExpressionHumansMaleModels, GeneticOdds RatioRiskStomach NeoplasmsSurvival AnalysisAMP-Activated Protein KinasesPRKAA1 protein, humanCancerMeta-analysisPolymorphismPRKAA1

Identifiers

PMID30340465
PMCPMC6194619
OpenAlexW2897815770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.